Surabhi Sutaria

Yes. Hi. Thanks for the opportunity. So I have two questions. One, your other APIs, the non - Ibuprofen has now crossed a INR200 crores kind of quarterly run rate, which is not seen in the last few quarters. So one, what is driving that growth? And second, of the INR200 crores in the non-Ibu segment, how much of it is regulated market and how much more can we supply to the regulated markets? Thank you.

Got it. Yes. Just last question in the non -- sorry, just last question in the non-ibuprofen. What is our biggest API? Is it clopidogrel? Is it pantoprazole? Which one is contributing the most?